Plus Orthopedics No Longer Facing FDA “Application Integrity” Restrictions
This article was originally published in The Gray Sheet
Smith & Nephew's new subsidiary Plus Orthopedics was removed from FDA's Application Integrity Policy (AIP) list Sept. 14 after three years of working with the agency to resolve its clinical trial issues
You may also be interested in...
Smith & Nephew will double its share of the European orthopedic reconstructive implant market with its $889 million acquisition of Plus Orthopedic Holding
Device companies showed marked improvement in complying with FDA clinical trial regulations during the past year, according to FDA
FDA has initiated disqualification proceedings against three orthopedic surgeons serving as clinical investigators in the last three months